Open this publication in new window or tab >>Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solna, Sweden..
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Affinity Proteomics. KTH, Centres, Science for Life Laboratory, SciLifeLab.
Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solna, Sweden..
Karolinska Inst, Sci Life Lab, Dept Med Biochem & Biophys, Div Genome Biol, Solna, Sweden.;Karolinska Inst, Ming Wai Lau Ctr Reparat Med, Stockholm Node, Solna, Sweden..
Karolinska Inst, Sci Life Lab, Dept Med Biochem & Biophys, Div Genome Biol, Solna, Sweden.;Karolinska Inst, Ming Wai Lau Ctr Reparat Med, Stockholm Node, Solna, Sweden..
Stockholm Univ, Dept Biochem & Biophys, Sci Life Lab, Solna, Sweden..
Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Div Internal Med, Danderyd, Sweden..
Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Div Internal Med, Danderyd, Sweden..
Karolinska Univ Hosp, Karolinska Univ Lab, Stockholm, Sweden..
Karolinska Univ Hosp, Karolinska Univ Lab, Stockholm, Sweden..
Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Affinity Proteomics.
Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solna, Sweden..
KTH, Centres, Science for Life Laboratory, SciLifeLab.
Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solna, Sweden..
KTH, Centres, Science for Life Laboratory, SciLifeLab. KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Affinity Proteomics.
KTH, Centres, Science for Life Laboratory, SciLifeLab. KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Affinity Proteomics.
Show others...
2021 (English)In: Nature Communications, E-ISSN 2041-1723, Vol. 12, no 1, article id 3695Article in journal (Refereed) Published
Abstract [en]
Serological testing is essential to curb the consequences of the COVID-19 pandemic. However, most assays are still limited to single analytes and samples collected within healthcare. Thus, we establish a multianalyte and multiplexed approach to reliably profile IgG and IgM levels against several versions of SARS-CoV-2 proteins (S, RBD, N) in home-sampled dried blood spots (DBS). We analyse DBS collected during spring of 2020 from 878 random and undiagnosed individuals from the population in Stockholm, Sweden, and use classification approaches to estimate an accumulated seroprevalence of 12.5% (95% CI: 10.3%-14.7%). This includes 5.4% of the samples being IgG(+)IgM(+) against several SARS-CoV-2 proteins, as well as 2.1% being IgG(-)IgM(+) and 5.0% being IgG(+)IgM(-) for the virus' S protein. Subjects classified as IgG(+) for several SARS-CoV-2 proteins report influenza-like symptoms more frequently than those being IgG(+) for only the S protein (OR=6.1; p<0.001). Among all seropositive cases, 30% are asymptomatic. Our strategy enables an accurate individual-level and multiplexed assessment of antibodies in home-sampled blood, assisting our understanding about the undiagnosed seroprevalence and diversity of the immune response against the coronavirus. Here, Roxhed et al. develop a multiplexed approach to screen IgG and IgM levels against several SARS-CoV-2 proteins in home-sampled dried blood spots and estimate seroprevalence of 12.5% in Stockholm in spring of 2020.
Place, publisher, year, edition, pages
Springer Nature, 2021
National Category
Infectious Medicine
Identifiers
urn:nbn:se:kth:diva-299050 (URN)10.1038/s41467-021-23893-4 (DOI)000665032700017 ()34140485 (PubMedID)2-s2.0-85108119441 (Scopus ID)
Note
QC 20210730
2021-07-302021-07-302026-01-15Bibliographically approved